Cadre (CDRE) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
8 Nov, 2026Executive summary
Q3 net sales rose 30.2% YoY to $202.9M; net income increased 46.1% to $16.0M and Adjusted EBITDA rose to $41.1M, with margin up 110 bps to 20.2%.
Organic growth was 10% excluding Distribution, supported by stronger EOD demand and acquisitions; backlog reached $338.2M at September 30, up $148.4M from year-end.
FY 2026 sales and Adjusted EBITDA guidance increased for a second consecutive quarter.
Financial highlights
Q3 gross profit was $88.1M, up 32%; gross margin was 43.4%, up 70 bps YoY.
Q3 diluted EPS was $0.37 vs. $0.27; operating income was $28.4M vs. $18.7M.
9M sales rose 27.6% to $565.4M and Adjusted EBITDA increased to $104.2M from $77.3M; net income fell to $29.4M from $32.4M.
9M operating cash flow was $67.6M vs. $42.5M; capital expenditures were $9.3M vs. $3.6M.
Q3 SG&A rose 29.0% YoY to $58.9M, mainly from acquisitions and higher compensation.
Outlook and guidance
FY 2026 net sales guidance increased to $756M–$769M from $749M–$769M; Adjusted EBITDA guidance rose to $140M–$144M from $139M–$144M.
Guidance midpoint implies sales growth of 24.9% and Adjusted EBITDA growth of 27.1%; FY 2026 capital expenditure outlook is $11M–$14M.
Full-year organic revenue growth is expected at 3%–4%; midpoint guidance implies Q4 revenue of ~$197M and Adjusted EBITDA margin of ~19%.
Backlog was $338.2M at September 30, 2026, versus $189.8M at December 31, 2025; $180.8M of remaining performance obligations includes ~53% expected within 12 months.
Latest events from Cadre
- Steady growth, disciplined M&A, and operational excellence drive leadership in safety markets.CDRE
Jefferies Global Industrials Conference 2026 - Strong Q2 2026 results and raised FY2026 outlook reflect robust growth and successful M&A.CDRE
Investor presentation - Q2 net sales up 32%, adjusted EBITDA up 56%, record backlog, and guidance raised.CDRE
Q2 2026 - Record backlog and robust growth in safety and nuclear markets drive strong 2026 outlook.CDRE
Investor presentation - Supplement amends 2025 executive compensation details; all other proxy matters remain unchanged.CDRE
Proxy filing - Q1 2026 net sales up 19%, record backlog, and major acquisitions support strong outlook.CDRE
Q1 2026 - Proxy covers director elections, auditor ratification, executive pay, and governance practices.CDRE
Proxy filing - Strong FY2025 results and disciplined M&A fuel growth, with FY2026 sales guidance up to $758M.CDRE
Investor presentation - Record EBITDA and net income growth in 2025, with double-digit 2026 outlook and higher dividend.CDRE
Q4 2025